newsfilter

$ELN News

Last published 12y ago

  • 12y agoELNPerrigo Company plc Completes Acquisition of Elan Corporation, plcBusiness WireDUBLIN--(BUSINESS WIRE)--Perrigo Company plc (NYSE, TASE: PRGO) (“Perrigo”) and Elan Corporation, plc (“Elan”) today announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6 billion. The transaction will create a global healthcare company with an industry-leading growth profile and the geographic sca ...
  • 12y agoPRGOELNPerrigo Company and Elan Corporation Plc Receive Irish High Court Approval for Perrigo’s Proposed Acquisition of ElanBusiness WireALLEGAN, Mich. & DUBLIN--(BUSINESS WIRE)--Perrigo Company (NYSE:PRGO; TASE) and Elan Corporation, plc (NYSE:ELN) (“Elan”) today announced that the Irish High Court has approved Perrigo’s pending acquisition of Elan.
  • 12y agoELNElan Announces Shareholder Approval of its Acquisition by Perrigo CompanyBusiness WireDUBLIN--(BUSINESS WIRE)--The shareholders of Elan Corporation, plc (NYSE:ELN) ("Elan") today overwhelmingly approved the acquisition of Elan by Perrigo Company (“Perrigo”) (NYSE, TASE: PRGO) at two special meetings of Elan shareholders: a special court-ordered meeting (the "Court Meeting") and an extraordinary general meeting (the "EGM").
  • 13y agoELNElan Reports Third Quarter 2013 Financial ResultsBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) today reported its third quarter and first nine months 2013 financial results.
  • 13y agoELNElan Announces Webcast of Third Quarter 2013 Financial ResultsBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Thursday, October 24, 2013 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan’s third quarter 2013 financial results, which will be released before the European and U.S. financial markets open.
  • 13y agoELNElan Announces Dates of Shareholder Meetings in Connection with Scheme of ArrangementBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) today announced that it has scheduled shareholder meetings for Monday, November 18, 2013 in connection with Perrigo Company’s (NYSE, TASE: PRGO) (“Perrigo”) proposed acquisition of Elan.
  • 13y agoELNElan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down SyndromeBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) announced today the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Study ELND005-DS201 will evaluate the safety and pharmacokinetics of 2 doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioural measures. Information on the study design a ...
  • 13y agoELNPerrigo Files Registration Statement on Form S-4 in Connection with Proposed Acquisition of ElanBusiness WireALLEGAN, Mich. & DUBLIN--(BUSINESS WIRE)--Perrigo Company (NYSE, TASE: PRGO) (“Perrigo”) and Elan Corporation, plc. (NYSE:ELN) (“Elan”) today announced that Perrigo Company Limited ("New Perrigo") has filed with the U.S. Securities and Exchange Commission (SEC) a registration statement on Form S-4 in connection with Perrigo's proposed acquisition of Elan, which included a joint proxy statement of ...
  • 13y agoELNElan Reports Second Quarter and First Half 2013 Financial ResultsBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) today reported its second quarter and first half 2013 financial results.
  • 13y agoELNFDA Grant Fast Track Designation to ELND005 for the Treatment of Neuropsychiatric Symptoms in Alzheimer’s DiseaseBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to its development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms (NPS) in Alzheimer’s disease (AD). The FDA concluded that the development program for ELND005 for the treatment of NPS in AD meet ...
  • 13y agoELNElan Announces Webcast of Second Quarter 2013 Financial ResultsBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, July 24, 2013 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan’s second quarter 2013 financial results, which will be released before the European and U.S. financial markets open.
  • 13y agoELNElan Advises Shareholders to Withdraw Any Acceptances of the Royalty Pharma Offer and Not to Tender Any Further Acceptances into This Lapsed Offer*Business WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan or the Company) today advises Elan Shareholders to withdraw any acceptances of Royalty Pharma’s Offer without delay and not to tender any further acceptances. Following the outcome of the Elan EGM yesterday morning, and in accordance with the terms of the Royalty Pharma Offer, the Royalty Pharma Offer has now lapsed*.
  • 13y agoELNElan Announces Results of EGMBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) (Elan or the Company) announces that, at its Extraordinary General Meeting held earlier today, shareholders approved the Share Repurchase Program.
  • 13y agoELNElan To Proceed with Formal Sale ProcessBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) (Elan or the Company) today announced that it is proceeding with a formal sale process in light of the expressions of interest received to date. As part of this process, Royalty Pharma will be invited to participate if they so wish. Accordingly, shareholders are urged not to tender into the current Royalty Pharma hostile offer.
  • 13y agoELNElan Issues Open Letter Urging Shareholders to Vote Today IN FAVOR of All Four EGM ResolutionsBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) (Elan or the Company) today issued a letter urging shareholders to protect the value of their investment in Elan by rejecting Royalty Pharma’s grossly inadequate offer to acquire Elan and by voting FOR all four resolutions in connection with Elan’s fast approaching Extraordinary General Meeting (EGM).
  • 13y agoELNElan Withdraws Lawsuit – Royalty Pharma Made Significant Additional DisclosureBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) today announced a successful result in the litigation Elan commenced one week ago in the United States District Court for the Southern District of New York (the “Court”) to compel corrective disclosure in Royalty Pharma’s tender offer documents. Elan is withdrawing its complaint before the Court because Royalty Pharma, in response t ...
  • 13y agoELNElan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender OfferBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan or the Company) today announced that its Board of Directors, after careful review and consideration and with the assistance of its executive management team as well as outside financial and legal advisors, has rejected the revised bid from privately held investment firm Royalty Pharma, through its subsidiary Echo Pharma Acquisition L ...
  • 13y agoELNElan’s Response to Royalty Pharma AnnouncementBusiness WireDUBLIN--(BUSINESS WIRE)--The Board of Elan Corporation, plc (NYSE:ELN) (Elan) notes today’s announcement regarding the revised offer by Echo Pharma Acquisition Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.5 of the Irish Takeover Rules.
  • 13y agoELNElan’s Response to Irish Takeover Panel RulingsBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) notes today's ruling by the Irish Takeover Panel (the "Panel") that Royalty Pharma must lapse its offer for Elan if any of the resolutions being put to Elan's EGM on June 17, 2013 are passed.
  • 13y agoELNElan Injunction; Royalty Pharma Issues Grossly Misleading Statement; Elan to Pursue Royalty Pharma's Misrepresentations and Lack of Disclosure with Relevant Authorities; US District Court Issues Temporary Restraining OrderBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) announces that earlier today Royalty Pharma issued a grossly misleading statement regarding the outcome yesterday of Elan's Irish High Court proceedings. On June 3, 2013, the Court prohibited Royalty Pharma from disseminating a Proxy Statement which, Elan believes, breached the Irish Takeover Rules. Yesterday, Royalty Pharma confirm ...
  • 13y agoELNElan Announces Outcome of Irish High Court InjunctionBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) confirms that Royalty Pharma has this afternoon (Irish time) agreed not to further disseminate its proxy statement, which the Irish High Court on June 3, 2013 restrained Royalty Pharma from distributing to Elan shareholders, until the Irish Takeover Panel has reviewed the contents of the proxy statement for compliance with Irish Tak ...
  • 13y agoELNElan Awarded Injunction against Royalty Pharma in IrelandBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) this afternoon (Irish time) received injunctive relief from the Irish High Court restraining Echo Pharma Acquisition Limited (Royalty Pharma's bid vehicle) from distributing to Elan's shareholders a proxy statement filed with the United States Securities and Exchange Commission at 10.18 p.m. (Irish time) on Friday 31 May 2013. Elan's compl ...
  • 13y agoELNElan Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised OfferBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) today issued a formal response document in respect of the Echo Pharma Acquisition Limited (Royalty Pharma) revised offer made on May 23, 2013. The response document is available on Elan’s website at www.elan.com.
  • 13y agoELNElan to Present at the Jefferies 2013 Global Healthcare ConferenceBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5, 2013 at 9:30 a.m. Eastern Time (ET), 2:30 p.m. British Summer Time (BST).
  • 13y agoELNElan Provides Shareholders with Categorical View on ValueBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) today is providing its shareholders and the market with an assessment of Tysabri’s value and Elan’s cash.
  • 13y agoELNElan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021Business WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced the pricing of the offering of US$850 million aggregate principal amount of 6.250% Senior Notes due 2021 (the “Notes”) by its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp. The Notes will be issued at par. The offering is expected to close on May 31, 2013, subject to customary ...
  • 13y agoELNElan Corporation, plc’s Board of Directors Unanimously Reject Royalty Pharma’s Revised Tender OfferBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) today announced that its Board of Directors, after careful review and consideration and with the assistance of its executive management team as well as outside financial and legal advisors, has determined that privately held investment firm Royalty Pharma's revised offer (“Royalty Pharma Offer") announced on Monday May 20, 2013 to a ...
  • 13y agoELNElan’s Response to Royalty Pharma AnnouncementBusiness WireDUBLIN--(BUSINESS WIRE)--The Board of Elan Corporation, plc (NYSE : ELN) (Elan) notes today’s announcement regarding the revised offer by Echo Pharma Acquisition Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.5 of the Irish Takeover Rules.
  • 13y agoELNElan Announces Proposed Offering of US$800.0 Million in Aggregate Principal Amount of Senior Notes Due 2021Business WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its wholly-owned subsidiaries, Elan Finance public limited company (“Elan Finance”) and Elan Finance Corp. (“Elan Corp.” and together with Elan Finance, the “Issuers”), intend to offer, subject to market conditions, US$800.0 million in aggregate principal amount of Senior Notes due 2021 (the “Notes”). The Note ...
  • 13y agoELNElan Announces Transactions: Decisively Transforming the CompanyBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) today announces a series of transactions designed to decisively transform and advance the company. Upon shareholder approval, the totality of these strategically driven decisions, in addition to the Theravance royalty participation agreement and dividend pass through announced last week and the previously completed Tysabri transacti ...
  • 13y agoELNElan Announces Publication of Response DocumentBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE : ELN) (Elan) today announces publication of a response document in respect of the Echo Pharma Acquisition Limited (Royalty Pharma) offer made on May 2, 2013.
  • 13y agoELNElan Provides Additional Commentary on Elan/Theravance Royalty Participation AgreementBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) provides additional commentary on today’s royalty participation agreement announcement between Elan and Theravance. As announced, Elan will make a one-time cash payment of $1.0 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from four respiratory programs Theravance has par ...
  • 13y agoTHRXELNTheravance and Elan Enter Into a $1.0 Billion Royalty Participation AgreementBusiness WireSOUTH SAN FRANCISCO, Calif. & DUBLIN--(BUSINESS WIRE)--Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN) today announced that they have entered into a royalty participation agreement wherein Elan will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc (GSK): RELVAR™ ELLIPTA™/BREO™ ELLIPT ...
  • 13y agoELNElan Announces Publication of Notice of 2013 Annual General Meeting & Directors’ RetirementBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (“Elan” or the “Company”) today publishes the Notice of the 2013 Annual General Meeting of the Company (the “AGM”). The Notice of AGM together with a Form of Proxy has been issued to shareholders. The 2013 AGM will be held at The Shelbourne Hotel, 27 St. Stephen’s Green, Dublin 2, Ireland on Thursday, 30 May 2013 at 10.00 a.m. Details of t ...
  • 13y agoELNElan Reports First Quarter 2013 Financial ResultsBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc today reported its first quarter 2013 financial results.
  • 13y agoELNElan Corporation, plc’s Board of Directors Unanimously Reject Royalty Pharma’s Unsolicited Tender OfferBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) today announced that its Board of Directors, after careful review and consideration and with the assistance of its executive management team as well as outside financial and legal advisors, has determined that privately held investment firm Royalty Pharma's offer, through its shell subsidiary Echo Pharma Acquisition Limited, to acqu ...
  • 13y agoELNElan Announces Final Results of its Tender OfferBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) (Elan) today announced the final results of its modified Dutch auction Tender Offer, to purchase its Ordinary Shares, including Ordinary Shares represented by American Depositary Shares (Shares), up to a maximum aggregate cost of US$1.0 billion, which closed at 8:00 a.m., Irish time, on April 18, 2013.
  • 13y agoELNElan’s Response to Royalty Pharma AnnouncementBusiness WireDUBLIN--(BUSINESS WIRE)--The Board of Elan Corporation, plc (NYSE : ELN) (Elan) notes this morning’s announcement regarding the offer by Echo Pharma Acquisition Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.5 of the Irish Takeover Rules.
  • 13y agoELNElan EGM Resolution Passed with over 99% ApprovalBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) announces that, at an Extraordinary General Meeting (EGM) held earlier today, the sole ordinary resolution to approve the Tender Offer to purchase Ordinary Shares (including Ordinary Shares represented by American Depositary Shares) was overwhelmingly passed with over 99% of the shares voted in favor of the resolution. The full text of the ...
  • 13y agoELNElan Announces Webcast of First Quarter 2013 Financial ResultsBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, April 24, 2013 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan’s first quarter 2013 financial results, which will be released before the European and U.S. financial markets open.
  • 13y agoELNElan Welcomes Irish Takeover Panel StatementBusiness WireDUBLIN--(BUSINESS WIRE)--The Board of Elan Corporation, plc (NYSE:ELN) (the Company) welcomes this morning's imposition by the Irish Takeover Panel of an expected May 10, 2013 deadline on Royalty Management LLC (Royalty Pharma) (following their original indication of interest announcement of February 25, 2013) by which Royalty Pharma must either announce an offer for Elan under Rule 2.5 of the Iri ...
  • 13y agoELNElan Announces Redemption of Its Senior Notes Due 2019Business WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) (the Company) announced today that it has issued an irrevocable Notice of Redemption to redeem all of the $600 million in aggregate principal amount of outstanding 6.25% Senior Notes due 2019 (the “Notes”) of its wholly owned subsidiaries, Elan Finance public limited company and Elan Finance Corp. The redemption is expected to occur on May ...
  • 13y agoELNElan Announces Closing of TYSABRI® Collaboration Transaction with Biogen IdecBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) is pleased to announce the closing today of the TYSABRI® (natalizumab) Collaboration Transaction with Biogen Idec. The agreement was announced on February 6, 2013.
  • 13y agoBIIBELNADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody StatusBusiness WireWESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results from several studies of TYSABRI® (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopa ...
  • 13y agoBIIBELNNew TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody StatusBusiness WireWESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results from several studies of TYSABRI® (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopa ...
  • 13y agoELNElan Discloses Filing of Share Repurchase Tender Offer DocumentationBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) (the Company) today disclosed the Tender Offer documentation for the Share Repurchase has been filed and is available on the Company’s website at www.elan.com.
  • 13y agoELNElan Provides Update on Tysabri Transaction and $1bn Share RepurchaseBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) (the Company) today provides an update on the Tysabri Restructuring Transaction (“the Tysabri Transaction”) announced on February 6, 2013 and further information regarding the Company’s recently announced proposed $1billion share repurchase program.
  • 13y agoELNElan’s Response to Royalty Pharma Statement of TodayBusiness WireDUBLIN--(BUSINESS WIRE)--The Board of Elan Corporation, plc (NYSE:ELN) (the Company) acknowledges this morning's statement by Royalty Management, LLC (Royalty Pharma). Elan’s position remains as outlined on February 25, 2013:
  • 13y agoELNElan Announces Further Unlocking of Value To Benefit ShareholdersBusiness WireDUBLIN--(BUSINESS WIRE)--The Board of Elan Corporation, plc (NYSE:ELN) (the Company) has approved the decision to initiate a unique cash dividend policy enabling its shareholders to benefit directly from the long term cash flow generated by Tysabri.
  • 13y agoELNElan Announces the Appointment of Mr. John Given as General CounselBusiness WireDUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) today announced the appointment of Mr. John Given as General Counsel with effect from 1 March, 2013. Mr. Given will report to the CEO, serve as a member of Elan’s executive management team as well as serve as advisor to the Chairman and the full Board. He will be based in Elan’s Dublin headquarters office.